In this article, we discuss the 5 best healthcare stocks under $20 according to Michael Castor’s Sio Capital. If you want to see our detailed analysis of Castor’s history, investment philosophy, and hedge fund performance, go directly to 10 Best Healthcare Stocks Under $20 According to Michael Castor’s Sio Capital.
5. Affimed N.V (NASDAQ:AFMD)
Castor’s Stake Value: $6.07 million
Percentage of Michael Castor’s 13F Portfolio: 1.51%
Number of Hedge Fund Holders: 25
Stock Price as of September 23: $6.26
Affimed N.V. (NASDAQ:AFMD) is a clinical-stage biopharmaceutical company that focuses on the discovery and development of immunotherapies for the treatment of cancer. Ranked fifth on our list of the 10 best healthcare stocks under $20 according to Michael Castor’s Sio Capital, Affimed N.V (NASDAQ:AFMD) has a market capitalization of $749.52 million.
Michael Castor’s Sio Capital Management currently holds 714,576 shares of Affimed N.V (NASDAQ:AFMD), amounting to over $6.07 million in worth and accounting for 1.51% of the fund’s portfolio. By the end of the second quarter of 2021, 25 hedge funds out of the 873 tracked by Insider Monkey held stakes in Affimed N.V (NASDAQ:AFMD) worth roughly $240.7 million. This is compared to 23 hedge funds in the previous quarter with a total stake value of approximately $262 million.
On September 8, Affimed N.V (NASDAQ:AFMD) issued its quarterly earnings report for the second quarter of 2021, with reported earnings per share at -$0.19, missing market estimates by $0.08. The company also reported revenues of $11.47 million, surpassing estimated revenues by $2.44 million.
On April 12, investment advisory BMO Capital maintained an Outperform rating on Affimed N.V. (NASDAQ:AFMD) stock and raised the price target to $15 from $12, highlighting positive results regarding the drugs being developed by the company.
4. Spruce BioSciences, Inc. (NASDAQ:SPRB)
Castor’ Stake Value: $7.25 million
Percentage of Michael Castor’s 13F Portfolio: 1.8%
Number of Hedge Fund Holders: 10
Stock Price as of September 23: $6.27
Spruce Biosciences, Inc. (NASDAQ:SPRB) is a late-stage biotechnology company that offers endocrinology services, and is involved in the development of medicines and therapies for the treatment of rare endocrine disorders. Ranked fourth on the list of the 10 best healthcare stocks under $20 according to Michael Castor’s Sio Capital, Spruce BioSciences, Inc. (NASDAQ:SPRB) has a market capitalization of $146.58 million.
At present, Michael Castor’s Sio Capital Management holds 647,239 shares of Spruce BioSciences, Inc. (NASDAQ:SPRB), worth over $7.25 million and representing 1.8% of the fund’s total portfolio. By the end of the second quarter of 2021, 10 hedge funds out of the 873 tracked by Insider Monkey held stakes in Spruce BioSciences, Inc. (NASDAQ:SPRB) worth roughly $72.7 million. This is compared to 8 hedge funds in the previous quarter with a total stake value of approximately $84 million.
For the second quarter of 2021, Spruce BioSciences, Inc. (NASDAQ:SPRB) reported earnings per share at -$0.50, falling short of the market estimates by $0.05.
Out of the hedge funds being tracked by Insider Monkey’s database, Illinois-based investment firm Citadel Investment Group is a leading shareholder in Spruce BioSciences, Inc. (NASDAQ:SPRB) with over 1.7 million shares worth more than $19 million.
3. Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)
Castor’s Stake Value: $7.86 million
Percentage of Michael Castor’s 13F Portfolio: 1.95%
Number of Hedge Fund Holders: 12
Stock Price as of September 23: $18.49
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) is a clinical-stage biotech company that focuses on the development and commercialization of a late-stage therapies and medication for the treatment of various cholestatic liver diseases. Ranked third on the list of the 10 best healthcare stocks under $20 according to Michael Castor’s Sio Capital, Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has a market capitalization of $564.24 million.
According to the recent 13F Filings, Michael Castor’s Sio Capital Management holds 454,892 shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), amounting to over $7.86 million in worth and accounting for 1.95% of the fund’s portfolio. By the end of the second quarter of 2021, 12 hedge funds out of the 873 tracked by Insider Monkey held stakes in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) worth roughly $180.4 million. This is compared to 11 hedge funds in the previous quarter with a total stake value of approximately $208 million.
On August 5, Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) issued its quarterly earnings report for the second quarter of 2021, with reported earnings per share at -$1.45, missing market estimates by $0.37. The company also reported revenues of $11.0 million, surpassing estimated revenues by $9.16 million.
Out of the hedge funds being tracked by Insider Monkey’s database, Washington-based investment firm Frazier Healthcare Partners is a leading shareholder in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) with over 3.56 million shares worth more than $61.67 million.
On September 20, JPMorgan analyst Jessica Fye began coverage of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) with an Overweight rating and $30 price target.
2. Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH)
Castor’s Stake Value: $14.86 million
Percentage of Michael Castor’s 13F Portfolio: 3.69%
Number of Hedge Fund Holders: 18
Stock Price as of September 23: $8.15
Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) is a Georgia-based holding company that provides various pediatric and healthcare services, including rehabilitation and therapy. Ranked second on our list of the 10 best healthcare stocks under $20 according to Michael Castor’s Sio Capital, Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) has a market capitalization of $1.50 billion.
Michael Castor’s Sio Capital currently holds over 1.2 million shares of Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH), amounting to approximately $14.86 million in worth and accounting for 3.69% of the fund’s total portfolio value. By the end of the second quarter of 2021, 18 hedge funds out of the 873 tracked by Insider Monkey held stakes in Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) worth roughly $168.9 million.
The holding company issued its quarterly earnings report for the second quarter of 2021 on August 11, with reported earnings per share at $0.10, in-line with the estimates for the quarter. Additionally, the company reported revenues of $436.11 million, beating market estimates by $2.11 million.
On May 27, Barclays analyst Steve Valiquette lowered the firm’s price target on Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) to $19 from $20 and kept an Overweight rating on the shares, after the company released its Q1 results.
Out of the hedge funds being tracked by Insider Monkey’s database, New York-based investment firm Nut Tree Capital is a leading shareholder in Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) with over 3.6 million shares worth more than $44.5 million.
1. Curis, Inc. (NASDAQ:CRIS)
Castor’s Stake Value: $27.1 million
Percentage of Michael Castor’s 13F Portfolio: 6.75%
Number of Hedge Fund Holders: 24
Stock Price as of September 23: $8.00
Curis, Inc. (NASDAQ:CRIS) is a biopharmaceutical company that is involved in the development of therapeutics for the regeneration and restoration of human tissues and organs. Furthermore, the company develops drugs and additional medicine for the treatment of cancer. The company has a market capitalization of $732.77 million and is ranked first on the list of the 10 best healthcare stocks under $20 according to Michael Castor’s Sio Capital.
According to the recent 13F Filings, Michael Castor’s Sio Capital Management holds 3.36 million shares of Curis, Inc. (NASDAQ:CRIS), worth over $27.1 million and representing 6.75% of the fund’s total portfolio value. As of Q2 2021, 24 hedge funds have stakes in Curis, Inc. (NASDAQ: CRIS), worth $314.2 million. This is compared to 29 hedge funds in the preceding quarter with a total stake value of approximately $493 million.
On August 3, Curis, Inc. (NASDAQ:CRIS) issued its quarterly earnings report for the second quarter of 2021, with reported earnings per share at -$0.12, falling short of market estimates of -$0.11 by $0.01. In addition, the company reported revenues of $2.29 million, missing estimates by $0.26 million.
On May 13, B. Riley analyst Justin Walsh raised the firm’s price target on Curis, Inc. (NASDAQ:CRIS) to $22 from $19 and reiterated a Buy rating on the shares.
Out of the hedge funds being tracked by Insider Monkey’s database, Boston-based investment firm RA Capital Management is a leading shareholder in Curis, Inc. (NASDAQ:CRIS) with over 7.14 million shares worth more than $57.6 million.
You can also take a look at 20 Best Places to Invest in Rental Property in 2021 and 10 Stocks to Buy and Hold According to Bill Gates.
